Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Receivables - Other: 2020-2024

Historic Receivables - Other for Nurix Therapeutics (NRIX) over the last 5 years, with Nov 2024 value amounting to $5.0 million.

  • Nurix Therapeutics' Receivables - Other rose 112.50% to $1.7 million in Q3 2025 from the same period last year, while for Aug 2025 it was $1.7 million, marking a year-over-year increase of 112.50%. This contributed to the annual value of $5.0 million for FY2024, which is 25.00% up from last year.
  • As of FY2024, Nurix Therapeutics' Receivables - Other stood at $5.0 million, which was up 25.00% from $4.0 million recorded in FY2023.
  • Over the past 5 years, Nurix Therapeutics' Receivables - Other peaked at $7.5 million during FY2020, and registered a low of $900,000 during FY2021.
  • For the 3-year period, Nurix Therapeutics' Receivables - Other averaged around $3.3 million, with its median value being $4.0 million (2023).
  • As far as peak fluctuations go, Nurix Therapeutics' Receivables - Other plummeted by 88.00% in 2021, and later surged by 300.00% in 2023.
  • Nurix Therapeutics' Receivables - Other (Yearly) stood at $7.5 million in 2020, then plummeted by 88.00% to $900,000 in 2021, then increased by 11.11% to $1.0 million in 2022, then spiked by 300.00% to $4.0 million in 2023, then grew by 25.00% to $5.0 million in 2024.